Hims & Hers Health, Inc. (NYSE:HIMS) Holdings Raised by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA increased its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 26.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 23,129 shares of the company’s stock after purchasing an additional 4,898 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Hims & Hers Health were worth $559,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in shares of Hims & Hers Health by 11.1% during the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock valued at $489,817,000 after purchasing an additional 2,020,722 shares during the last quarter. State Street Corp increased its holdings in shares of Hims & Hers Health by 4.7% in the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company’s stock worth $85,221,000 after acquiring an additional 206,078 shares during the period. Geode Capital Management LLC lifted its position in Hims & Hers Health by 12.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after purchasing an additional 482,177 shares during the last quarter. Wellington Management Group LLP boosted its stake in Hims & Hers Health by 34.5% during the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after purchasing an additional 883,230 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in Hims & Hers Health by 7.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,796,838 shares of the company’s stock worth $43,448,000 after purchasing an additional 129,416 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Bank of America lifted their price target on Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a report on Tuesday, March 18th. Citigroup reiterated a “sell” rating on shares of Hims & Hers Health in a research report on Wednesday, April 2nd. Canaccord Genuity Group raised their price target on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. BTIG Research assumed coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective for the company. Finally, Piper Sandler raised their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday, February 25th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $37.31.

Hims & Hers Health Stock Performance

Hims & Hers Health stock opened at $26.02 on Wednesday. The firm has a market cap of $5.78 billion, a price-to-earnings ratio of 59.14 and a beta of 1.65. Hims & Hers Health, Inc. has a 1 year low of $11.20 and a 1 year high of $72.98. The firm’s 50 day moving average price is $39.53 and its two-hundred day moving average price is $30.15.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. As a group, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Irene Becklund sold 2,203 shares of Hims & Hers Health stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total transaction of $63,402.34. Following the transaction, the insider now owns 8,007 shares of the company’s stock, valued at $230,441.46. The trade was a 21.58 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Soleil Boughton sold 4,152 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total transaction of $251,984.88. Following the completion of the sale, the insider now directly owns 157,345 shares of the company’s stock, valued at $9,549,268.05. This trade represents a 2.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 809,806 shares of company stock valued at $30,923,658 over the last ninety days. Corporate insiders own 17.71% of the company’s stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.